Publicaciones en colaboración con investigadores/as de University of North Carolina at Chapel Hill (20)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (Nature Genetics, (2023), 55, 1, (89-99), 10.1038/s41588-022-01222-9)

    Nature Genetics

  2. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

    Nature Genetics, Vol. 55, Núm. 1, pp. 89-99

2022

  1. Review of the current evidence for topical treatment for venous leg ulcers

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 10, Núm. 1, pp. 241-247.e15

2021

  1. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

    The Lancet Neurology

  2. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

    European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171

2019

  1. Effects of serelaxin in patients with acute heart failure

    New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726

  2. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

    Nature Genetics, Vol. 51, Núm. 5, pp. 804-814

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Genome-wide associations for birth weight and correlations with adult disease

    Nature, Vol. 538, Núm. 7624, pp. 248-252

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  4. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89

2015

  1. A new strategy for enhancing imputation quality of rare variants from next-generation sequencing data via combining SNP and exome chip data

    BMC Genomics, Vol. 16, Núm. 1

  2. Defining breast cancer intrinsic subtypes by quantitative receptor expression

    Oncologist, Vol. 20, Núm. 5, pp. 474-482

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

  2. Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 36, pp. 13127-13132